137 related articles for article (PubMed ID: 11366764)
21. What they say about: protease inhibitors.
Posit Aware; 2000; 11(1):48-54. PubMed ID: 11366351
[TBL] [Abstract][Full Text] [Related]
22. FDA approves new dosing for amprenavir and ritonavir combination.
AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
[No Abstract] [Full Text] [Related]
23. Experimental drug available.
Vazquez E
Posit Aware; 1998; 9(6):17. PubMed ID: 11366472
[TBL] [Abstract][Full Text] [Related]
24. Using Agenerase. Nutritional considerations affect bioavailability of new P.I.
Tong C; Fenton M; Hall M
Posit Living; 1999 Jul; 8(6):6, 62. PubMed ID: 12492049
[No Abstract] [Full Text] [Related]
25. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
26. Amprenavir: a new protease inhibitor nears approval.
Highleyman L
BETA; 1999 Jan; 12(1):8-9. PubMed ID: 11367244
[TBL] [Abstract][Full Text] [Related]
27. Amprenavir: a review of its clinical potential in patients with HIV infection.
Noble S; Goa KL
Drugs; 2000 Dec; 60(6):1383-410. PubMed ID: 11152018
[TBL] [Abstract][Full Text] [Related]
28. Anti-HIV agents. Saquinavir with fosamprenavir.
TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
[No Abstract] [Full Text] [Related]
29. Four posters add to our knowledge of Lexiva.
Proj Inf Perspect; 2008 Dec; (47):7-8. PubMed ID: 19227558
[No Abstract] [Full Text] [Related]
30. [Second chance therapy. New protease inhibitor for salvage therapy].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():53. PubMed ID: 10863313
[No Abstract] [Full Text] [Related]
31. FDA notifications. Agenerase product label changed.
AIDS Alert; 2002 Oct; 17(10):131. PubMed ID: 12400469
[No Abstract] [Full Text] [Related]
32. FDA notifications. FDA approves NDA for Lexiva.
AIDS Alert; 2007 Dec; 22(12):142. PubMed ID: 18415960
[No Abstract] [Full Text] [Related]
33. FDA notifications. FDA approves new formulation of Lexiva.
AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
[No Abstract] [Full Text] [Related]
34. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
[No Abstract] [Full Text] [Related]
35. Fosamprenavir: drug development for adherence.
Hester EK; Chandler HV; Sims KM
Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
[TBL] [Abstract][Full Text] [Related]
36. Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
Kohli-Pamnani A; Huynh P; Lobo F
Ann Allergy Asthma Immunol; 2006 Apr; 96(4):620-3. PubMed ID: 16680935
[TBL] [Abstract][Full Text] [Related]
37. New expanded access drugs for use in combination therapy.
Newsline People AIDS Coalit N Y; 1998 Dec; ():22-3. PubMed ID: 11367085
[TBL] [Abstract][Full Text] [Related]
38. Amprenavir approved.
AIDS Patient Care STDS; 1999 Jul; 13(7):438. PubMed ID: 10870601
[No Abstract] [Full Text] [Related]
39. Lower dose of ritonavir approved for use with fosamprenavir.
Sax PE
AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
[No Abstract] [Full Text] [Related]
40. Drug interactions. Interactions with TMC114 and TMC125.
TreatmentUpdate; 2006; 18(3):8-9. PubMed ID: 17211920
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
